bpc-157 gary brecka Joe Rogan and dive into the FDA's reclassification of peptides, with lots of F-bombs along the way. Tune in to hear Gary's thoughts on why the FDA is doing this Imagine a compound that accelerates

It really would be life changing to have these at least reduced

However, we are also aware of the potential medication interactions that can occur with this treatment

Because angiogenesis is a defining hallmark of tumor growth and metastatic progression, any therapeutic agent that enhances neovascularization could, in theory, facilitate tumor expansion and promote metastatic dissemination

There is zero receptor overlap, meaning both compounds can work at full efficacy without interfering with each other

Support for Long COVID & Chronic Inflammation: Their combined anti-inflammatory effects may help manage chronic fatigue, systemic inflammation, and post-viral recovery